Manchester Pharma

Fort Collins, United States Founded: 2008 • Age: 18 yrs Acquired By Retrophin
Therapeutic modalities for ultra-rare diseases are developed and commercialized.

About Manchester Pharma

Manchester Pharma is a Healthcare company based in Fort Collins (United States) founded in 2008, and was acquired by Retrophin in February 2014. Therapeutic modalities for ultra-rare diseases are developed and commercialized. Its focus areas include Life Sciences, Rare Diseases, Drugs and GI. Its competitors include Phathom Pharmaceuticals, Lumena Pharma and Ellodi Pharmaceuticals; 2 of its 3 listed competitors have raised funding.

Company details

Manchester Pharmaceuticals was established in 2008 in Fort Collins, United States, as a specialty pharmaceutical firm. Focus is placed on identifying, developing, and commercializing treatments for ultra-rare diseases. Two FDA-approved products are marketed: Chenodal, a synthetic bile acid for gallstones in high-risk patients, and Vecamyl, tablets for managing severe essential hypertension. Acquisition by Retrophin occurred in February 2014.

Operational Areas
Key Metrics

Investors in Manchester Pharma

Manchester Pharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Retrophin.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Drugs are developed for debilitating and life-threatening diseases.
2011retrophin.comSan Diego, United States
Premium access

Investor details for Manchester Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Manchester Pharma

2 dated milestones of Manchester Pharma across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Manchester Pharma is founded.
  2. Exit Acquired by Retrophin.

Competitors of Manchester Pharma

Manchester Pharma has 3 listed competitors in our database, 2 of them funded. They include Phathom Pharmaceuticals, Lumena Pharma and Ellodi Pharmaceuticals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
phathompharma.com2019Menlo Park, United States$90M113
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals.
lumenapharma.com2011San Diego, United States$71.05M11
Passionately pursuing better treatments for adults and children with rare liver diseases.
ellodipharma.com2020Ewing Township, United States
Therapeutics for Eosinophilic Esophagitis are developed by Ellodi Pharmaceuticals.
Premium access

Detailed competitors of Manchester Pharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Rare Diseases

3 companies that operate in the same segment as Manchester Pharma (Rare Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Gene therapies for rare diseases including retinal dystrophies are developed.
2013Philadelphia, Pennsylvania, United StatesUSD 82.8 MUSD 64.73 M822
Therapeutics for genetic diseases are developed through targeted interventions.
2015Palo Alto, California, United StatesUSD 434.2 MUSD 502.08 M730
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Manchester Pharma

Manchester Pharma was founded in 2008.

Manchester Pharma is headquartered in Fort Collins, United States. It is registered at Fort Collins, Colorado, United States.

Manchester Pharmaceuticals was established in 2008 in Fort Collins, United States, as a specialty pharmaceutical firm. Focus is placed on identifying, developing, and commercializing treatments for ultra-rare diseases. Two FDA-approved products are marketed: Chenodal, a synthetic bile acid for gallstones in high-risk patients, and Vecamyl, tablets for managing severe essential hypertension. Acquisition by Retrophin occurred in February 2014.

Manchester Pharma's top competitors include Phathom Pharmaceuticals, Lumena Pharma and Ellodi Pharmaceuticals.

Manchester Pharma has 1 investor. Key investors include Retrophin.

Yes. Manchester Pharma was acquired by Retrophin in February 2014.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available